Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy - Archive ouverte HAL Access content directly
Journal Articles Targeted Oncology Year : 2017

Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy

(1, 2) , (3, 2) , (4) , (5) , (6, 7) , (8) , (9) , (4) , (10, 3) , (4) , (11, 12) , (13) , (3, 2) , (2, 3) , (2, 14) , (2, 14) , (2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Alain Ravaud

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is highly metastatic. Cabozantinib, an anti-angiogenic tyrosine kinase inhibitor that targets c-MET, provided interesting results in metastatic ccRCC treatment. Objective: To understand better the role of c-MET in ccRCC, we assessed its status in a population of patients with metastatic ccRCC. Patients and Methods For this purpose, tumor samples were analyzed for c-MET expression by immunohistochemistry (IHC), for c-MET copy number alterations by fluorescence in situ hybridization (FISH), and for c-MET mutations by next generation sequencing (NGS) in a retrospective cohort of 90 primary ccRCC of patients with metastases treated by first-line sunitinib. The expression of c-MET was correlated with pathological, immunohistochemical (VEGFA, CAIX, PD-L1), clinical, and molecular criteria (VHL status) by univariate and multivariate analyses and to clinical outcome using Kaplan-Meier curves compared by log-rank test. Results: Of ccRCC, 31.1% had low c-MET expression (absent to weak intensity by IHC) versus 68.9% with high expression (moderate to strong intensity). High expression of c-MET was associated with a gain in FISH analysis (p=0.0284) without amplification. No mutations were detected in NGS. Moreover, high c-MET expression was associated with lymph node metastases (p=0.004), sarcomatoid component (p=0.029), VEGFA (p=0.037), and PD-L1 (p=0.001) overexpression, the only factor that remained independently associated (p<0.001) after logistic regression. No difference was observed in clinical outcomes. Conclusion: This study is the first to analyse c-MET status in metastatic ccRCC. The high expression of c-MET in the majority of ccRCC and its independent association with PD-L1 expression, may suggest a potential benefit from combining c-MET inhibitors and targeted immunotherapy.
Fichier principal
Vignette du fichier
Kammerer-Correlation of c-MET expression with PD-L1-clean copy.pdf (275.21 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01578072 , version 1 (06-10-2017)

Identifiers

Cite

Solène-Florence Kammerer-Jacquet, Sarah Médane, Karim Bensalah, Jean-Christophe Bernhard, Mokrane Yacoub, et al.. Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy. Targeted Oncology, 2017, 12 (4), pp.487-494. ⟨10.1007/s11523-017-0498-1⟩. ⟨hal-01578072⟩
166 View
263 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More